Novartis a réalisé une bonne performance au premier trimestre et agi pour devenir une entreprise plus centrée sur les médicaments

NEXT STORY
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE “TRANSPARENCY LAW”)
PREV STORY
Curetis Launches CE-IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge at ECCMID 2018
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Novartis a réalisé une bonne performance au premier trimestre et agi pour devenir une entreprise plus centrée sur les médicaments

NEXT STORY
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE “TRANSPARENCY LAW”)
PREV STORY
Curetis Launches CE-IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge at ECCMID 2018
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

SciCann Therapeutics reports positive pre-clinical results for proprietary CBD combination product

TORONTO, Aug. 23, 2018 (GLOBE NEWSWIRE) -- SciCann Therapeutics Inc reports today positive results ...

author_avatar
NASDAQ Market News

VIFOR PHARMA CONCLUDES LICENSING AGREEMENT WITH ZERIA TO MARKET VELTASSA® IN JAPAN

Vifor Pharma gives Zeria exclusive rights to develop and market Veltassa® in Japan Potential ...

author_avatar
NASDAQ Market News

Veritas Pharma Initiates Cancer Research with Dr. Dmitri Petchkovski

VANCOUVER, British Columbia, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT); (OTC:VRTHF); ...

author_avatar
NASDAQ Market News